TABLE 6.

Preclinical in vivo studies of hMSCs used as advanced therapy for psoriasis in the last 5 years.

Type of advanced therapy	Cells	Type of hMSC treatment evaluated	Animals	Disease models	Follow-up	References
Cell therapy and gene therapy	hUCB-MSCs	1-hUCB-MSC group: 2 × 106 cells injected subcutaneously 24 h before and at day 6 of imiquimod application 2-hUCB-MSC-transduced group: 2 × 106 cells transduced with extracellular superoxide dismutase (SOD3) and injected subcutaneously 24 h before and at day 6 of imiquimod application 3-Control group: subcutaneous injections of an equal volume of phosphate-buffered saline at the same time points	– C57BL/6 mice	A mouse model of IMQ-induced psoriasis-like inflammation	12 days	Sah et al., 2016
Cell therapy	hUCB-MSCs	1-hUCB-MSC group: 2 × 106 cells were injected subcutaneously on day 1 and 7 after induction of psoriasis-like skin 2-Control group: subcutaneous injections of an equal volume of phosphate-buffered saline at the same time points	– C57/BL6 male mice	IL-23-mediated psoriasis-like skin inflammation mouse model IMQ-induced psoriasis-like skin inflammation mouse model	15 days	Lee et al., 2017
	hPT-MSCs	1-hPT-MSC group: 106 cells via the mouse tail vein on days 1 and 3 of the imiquimod application period 2-Control group: Mice received an intravenous injection of an equal volume of phosphate-buffered saline (PBS) via tail vein at the same time points	– Female C57BL/6 mice	IMQ-induced psoriasis-like skin inflammation mouse model	7 days	Kim J.Y. et al., 2018
	hA-MSCs	1-hA-MSC group: 2 × 105 cells injected intravenously 2-Control group: mouse serum injected intravenously	– B6 mice	A mouse model of IMQ-induced psoriasis-like inflammation	5 days	Imai et al., 2019
	hUCB-MSCs	1-hUCB-MSC group: 1 × 105 cells injected intravenously 2-Control group: phosphate-buffered saline injected intravenously	– Female BALB/c mice	A mouse model of IMQ-induced psoriasis-like inflammation	13 days	Chen et al., 2019